|p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis.|
|Jump to Full Text|
|PMID: 23303459 Owner: NLM Status: MEDLINE|
|Fibrosis, the hallmark of systemic sclerosis (SSc), is characterized by persistent fibroblast activation triggered by transforming growth factor-β (TGF-β). As the acetyltransferase p300 has a key role in fibrosis and its availability governs the intensity of fibrotic responses, we investigated p300 expression in SSc and the molecular basis of its regulation. We found that expression of p300 was markedly elevated in SSc skin biopsies and was induced by TGF-β in explanted normal skin fibroblasts. Stimulation of p300 by TGF-β was independent of Smads and involved the early-immediate transcription factor Egr-1 (early growth response 1), a key regulator of profibrotic TGF-β signaling. Indeed, Egr-1 was both sufficient and necessary for p300 regulation in vitro and in vivo. Increased p300 accumulation in TGF-β-treated fibroblasts was associated with histone hyperacetylation, whereas p300 depletion, or selective pharmacological blockade of its acetyltransferase activity, attenuated TGF-β-induced responses. Moreover, TGF-β enhanced both p300 recruitment and in vivo histone H4 acetylation at the COL1A2 (collagen, type I, α2) locus. These findings implicate p300-mediated histone acetylation as a fundamental epigenetic mechanism in fibrogenesis and place Egr-1 upstream in TGF-β-driven stimulation of p300 gene expression. The results establish a firm link between fibrosis with aberrant p300 expression and epigenetic activity that, to our knowledge, is previously unreported. Targeted disruption of p300-mediated histone acetylation might therefore represent a viable antifibrotic strategy.|
|Asish K Ghosh; Swati Bhattacharyya; Robert Lafyatis; Giuseppina Farina; Jianxiu Yu; Bayar Thimmapaya; Jun Wei; John Varga|
Related Documents :
|3259249 - Histological detection of messenger rnas with biotinylated synthetic oligonucleotide pr...
11680719 - Optimized t7 amplification system for microarray analysis.
25472249 - 200 stage-specific expression patterns of the insulin-like growth factor 1 receptor dur...
23545719 - Expression and localisation of osteopontin and prominin-1 (cd133) in patients with endo...
24465439 - Aberrant activation of the wnt/β-catenin signaling pathway in lupus nephritis.
15683919 - The peroxinectin of white shrimp litopenaeus vannamei is synthesised in the semi-granul...
23631859 - Starvation actively inhibits splicing of glucose-6-phosphate dehydrogenase mrna via a b...
22660929 - Stochastic branching-diffusion models for gene expression.
10199559 - Expression of insulin-like growth factor binding protein-3 (igfbp-3) in human keratinoc...
|Type: In Vitro; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2013-01-10|
|Title: The Journal of investigative dermatology Volume: 133 ISSN: 1523-1747 ISO Abbreviation: J. Invest. Dermatol. Publication Date: 2013 May|
|Created Date: 2013-04-18 Completed Date: 2013-07-09 Revised Date: 2014-07-17|
Medline Journal Info:
|Nlm Unique ID: 0426720 Medline TA: J Invest Dermatol Country: United States|
|Languages: eng Pagination: 1302-10 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Collagen Type I / metabolism
Early Growth Response Protein 1 / deficiency, genetics, metabolism
Epigenesis, Genetic / physiology*
Fibroblasts / drug effects, metabolism, pathology
Gene Expression Regulation / drug effects*
Histones / metabolism
Mice, Inbred C57BL
Scleroderma, Systemic / metabolism*, pathology, physiopathology
Skin / drug effects, metabolism*, pathology*
Smad3 Protein / deficiency, genetics, metabolism
Transforming Growth Factor beta / pharmacology*
p300-CBP Transcription Factors / genetics, metabolism*
|AR42309/AR/NIAMS NIH HHS; CA74403/CA/NCI NIH HHS; P50 AR060780/AR/NIAMS NIH HHS; R01 AR042309/AR/NIAMS NIH HHS; R01 AR051089/AR/NIAMS NIH HHS; R01 CA074403/CA/NCI NIH HHS; R03 AR062721/AR/NIAMS NIH HHS|
|0/Collagen Type I; 0/EGR1 protein, human; 0/Early Growth Response Protein 1; 0/Egr1 protein, mouse; 0/Histones; 0/Smad3 Protein; 0/Transforming Growth Factor beta; EC 184.108.40.206/p300-CBP Transcription Factors; EC 220.127.116.11/p300-CBP-associated factor|
Journal ID (nlm-journal-id): 0426720
Journal ID (pubmed-jr-id): 4839
Journal ID (nlm-ta): J Invest Dermatol
Journal ID (iso-abbrev): J. Invest. Dermatol.
nihms-submitted publication date: Day: 4 Month: 12 Year: 2012
Electronic publication date: Day: 10 Month: 1 Year: 2013
Print publication date: Month: 5 Year: 2013
pmc-release publication date: Day: 01 Month: 11 Year: 2013
Volume: 133 Issue: 5
First Page: 1302 Last Page: 1310
PubMed Id: 23303459
|p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis|
|Asish K Ghosh1ф|
1Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL
2Boston University, Boston, MA
3Department of Biochemistry and Molecular Cell Biology, SJTU-SM, Shanghai, China
4Department of Microbiology and Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL
|*Address for correspondence: Northwestern University Feinberg School of Medicine, Division of Rheumatology, 240 East Huron Street, Chicago, Illinois 60611. Tel: (312) 503-0368. Fax: (312) 503-0994. email@example.com or firstname.lastname@example.org
фPresent address: Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, Illinois 60611.
The ubiquitous nuclear phosphoprotein p300 is a component of the chromatin remodeling and transcriptional complex that modulates the expression of genes involved in cell cycle regulation, apoptosis, growth and development (Goodman and Smolik, 2000). The histone acetyltransferase (HAT) domain enables p300 to catalyze histone acetylation and augment activator-dependent transcription (Kraus and Kadonaga, 1998; Vo and Goodman, 2001). In addition to chromatin histone, p300 can also catalyze acetylation of early response gene-1 (Egr-1) and other transcription factors (Ghosh and Varga, 2007). While p300 is essential for normal embryogenesis, altered expression or function is implicated in the Rubinstein-Taybi syndrome, cancer, neurodegenerative diseases and other pathologies (Giles et al., 1998; Iyer et al., 2004; Janknecht, 2002; Petrij et al., 1995; Roelfsema et al., 2005; Saha and Pahan, 2006). Recent studies reveal important roles for p300 in the regulation of extracellular matrix (ECM) homeostasis, myofibroblast transformation and epithelial-mesenchymal transition (Ghosh and Varga, 2007; Kaimori et al., 2010; Lim et al., 2012; Yokomizo et al., 2011).
We have shown previously that the HAT activity of p300 and its interaction with activated Smads are essential for transforming growth factor -β (TGF-β)-induced profibrotic signaling (Ghosh et al., 2004; Ghosh et al., 2009; Ghosh et al., 2001; Ghosh et al., 2000). Moreover, levels of p300 are limiting in normal fibroblasts, and ectopic expression of p300 dramatically enhanced the magnitude of TGF-β responses, whereas ribozyme-mediated knockdown of cellular p300 resulted in selective abrogation of the stimulation of collagen gene expression. Levels of p300 were significantly elevated in explanted SSc fibroblasts (Bhattacharyya et al., 2005), and in skin from mice with chronic GVHD-associated skin fibrosis, suggesting that p300 might have an important role in the pathogenesis of SSc.
Surprisingly, the regulation of p300 expression and activity under physiological and pathological conditions have received scant attention. The present studies demonstrate that p300 expression was significantly elevated in SSc skin biopsies, and was markedly stimulated by TGF-β in explanted normal fibroblasts via a Smad-independent pathway. Increased p300 abundance in TGF-β-stimulated fibroblasts, as well as in cells conditionally overexpressing p300, was associated with p300 accumulation on target gene promoters, histone H4 acetylation and elevated Type I collagen transcriptional activity. These results establish an important mechanistic link between TGF-β signaling, excessive collagen gene expression and fibrosis that is mediated through Egr-1 induction of p300 and histone hyperacetylation at the collagen gene promoter. Precise delineation of the molecular events underlying fibrogenesis and the role of p300 in TGF-β-inducible transcriptional responses may accelerate the development of targeted therapies to control the progression of fibrosis in SSc.
We have previously shown that p300 levels were elevated in explanted SSc fibroblasts (Bhattacharyya et al., 2005). We confirmed this finding in additional fibroblasts from patients with dSSc (Fig. 1a). Next we evaluated biopsies of lesional skin from ten patients with SSc and of dorsal forearms from five healthy controls by immunohistochemistry. The results showed markedly increased p300 immunostaining in SSc biopsies (Fig. 1b). In the SSc lesional dermis, p300 was localized largely to the nucleus in fibroblast-like cells. Staining with isotype control antibodies indicated the specificity of anti-p300 antibodies. The intensity of cellular p300 staining in diffuse cutaneous SSc biopsies showed a modest positive correlation with the modified Rodnan skin score (slope=0.23, R2=0.29).
In view of the increased expression of p300 in SSc skin biopsies, and its pivotal role in mediating TGF-β-induced profibrotic responses, we investigated the regulation of p300 expression by TGF-β. The results of semi-quantitative PCR, Western blot and immunofluorescence analysis revealed that in normal fibroblasts, TGF-β enhanced the levels of p300 (Fig. 2a–b). Stimulation could be detected as early as 6 h, with a maximal >3-fold increase at 48 h. Remarkably, in contrast to p300, levels of CBP, a p300 paralogue with comparable histone acetyltransferase and coactivator function, remained unaltered in TGF-β-treated fibroblasts (data not shown). Northern analysis revealed that stimulation in p300 mRNA expression by TGF-β was concentration-dependent, with a maximal >3-fold increase (Fig. 2c).
A series of experiments were performed in neonatal and adult skin fibroblasts to address the mechanisms underlying p300 stimulation. To examine changes in the stability of p300 mRNA transcripts, fibroblasts were incubated with TGF-β in the presence or absence of actinomycin D (5 μg/ml), followed by determination of mRNA levels at the indicated intervals. The results of RT-PCR showed that p300 mRNA level declined at a comparable rate in the absence or presence of TGF-β, with an estimated half-life of 6–9 h (Fig. 2d). To evaluate the effect of TGF-β on p300 gene transcription, confluent NIH3T3 fibroblasts were transiently transfected with p300-luc reporter constructs. Following 24 h of incubation in serum-free media containing TGF-β, cultures were harvested and luciferase activities were determined. The results indicated that TGF-β induced a >2-fold stimulation of luciferase activity driven by a p300 promoter (Fig. 2e). Addition of serum strongly stimulated p300 promoter activity in transfected fibroblasts, consistent with previous reports in prostate cancer cells (Yu et al., 2004). Together, these results indicate that p300 gene expression is stimulated by TGF-β via transcriptional stimulation.
Pretreatment of the cultures with a selective inhibitor of AKL5-mediated Smad2/3 phosphorylation (SB431542) did not block the stimulation of p300 induced by TGF-β, while significantly reducing Smad2 phosphorylation (80% reduction in lane 6 compared to lane 2) (Fig. 3a). In sharp contrast, the ERK1/2 inhibitor PD98059 completely prevented the stimulation (Fig. 3a). Consistent with these results, TGF-β stimulated p300 mRNA levels with a comparable magnitude in Smad3 null and wildtype MEFs (90±18% in wildtype MEFs and 86±3% in Smad3−/− MEFs, p=n.s., data not shown). Moreover, transient transfection assays showed that the ERK1/2 inhibitor, but not the ALK5 inhibitor, abrogated the stimulation of p300 promoter activity (Fig. 3b). Identical Smad-independent TGF-β stimulation of p300 expression was seen in human adult skin fibroblasts incubated with TGF-β (Fig. 3c).
We demonstrated previously that expression of Egr-1 was stimulated by TGF-β in a variety of cell types in a rapid and transient manner and requiring ERK1/2, but not Smads (Bhattacharyya et al., 2011). Moreover, Egr-1 was both necessary and sufficient for TGF-β stimulation of collagen gene expression. Inspection of the human p300 gene promoter revealed the presence of multiple conserved Egr-1 recognition sites (data not shown), suggesting a potential role for Egr-1 in regulation of p300. To investigate this possibility directly, Egr-1 was ectopically expressed in normal fibroblasts with/without TGF-β. The results from multiple transfection assays demonstrated that Egr-1 by itself was capable of enhancing p300 expression, with a magnitude of stimulation comparable to that induced by TGF-β (Fig. 4a). To define the role of DNA-binding activity of Egr-1 in mediating transactivation, we used a mutant p300 promoter construct harboring base changes disrupting all six Egr-1 binding sites (Yu et al., 2004). Transient transfection of this Egr-1-unresponsive mutant p300 promoter revealed reduced basal transcriptional activity, and importantly, complete abrogation of the TGF-β stimulatory response (Fig. 4b). Next, to directly examine the role of Egr-1 in p300 regulation, we used fibroblasts lacking Egr-1. For this purpose, MEFs from Egr-1−/− mice and Egr-1+/+ wildtype littermates in parallel were grown to confluence and then incubated with TGF-β. Western analysis revealed that absence of cellular Egr-1 was associated with decreased levels of p300, and a substantial loss of the TGF-β stimulatory response (Fig. 4c). The role of Egr-1 in TGF-β-induced p300 expression was next examined in vivo. For this purpose, Egr-1−/− mice and wildtype littermates were injected in parallel with TGF-β. Analysis of mRNA directly isolated from the injected skin revealed that in the absence of Egr-1, TGF-β failed to induce p300 expression in vivo (Fig. 4d). Consistent results at the level of protein expression were obtained by immunofluorescence (Fig. 4e). The results from these in vitro and in vivo experiments collectively establish the indispensible role of Egr-1 in the regulation of p300 by TGF-β.
Maximal stimulation of collagen synthesis by TGF-β depends on the acetyltransferase activity of p300 (Ghosh et al., 2000). In light of its importance, we sought to investigate the role of p300-mediated histone H4 acetylation in fibrotic responses elicited by TGF-β. Confluent fibroblasts were incubated with TGF-β for 24 h, and total cellular histones were acid-extracted. Western analysis showed that TGF-β induced a significant increase in acetylated histone H4, whereas levels of total histone H4 remained unaltered (Fig. 5a). The role of p300 in TGF-β-induced histone hyperacetylation was further evaluated by complementary gain-of-function and loss-of-function experiments. Ad-Tet infection of fibroblasts stably expressing inducible p300 resulted in markedly increased accumulation of p300 in these cells, which was associated with significantly enhanced histone H4 acetylation (Fig. 5b). To further examine the contribution of p300 in the TGF-β response, endogenous p300 was knocked down in normal dermal fibroblasts using p300-specific ribozymes. The results of Western analysis demonstrated that while TGF-β treatment resulted in increased histone H4 acetylation in control fibroblasts, ribozyme-mediated depletion of cellular p300 substantially abrogated the response (Fig. 5c). The effects of TGF-β on the recruitment of p300 to the COL1A2 promoter, and associated locus-specific histone acetylation in vivo, were examined next. The results of ChIP assays revealed markedly elevated p300 accumulation and histone H4 acetylation at the Smad binding region of COL1A2 promoter in fibroblasts incubated with TGF-β (Fig. 6a).
To directly establish the functional significance of the acetyltransferase activity of p300 in the fibrotic responses elicited by TGF-β, we used anacardic acid, a selective pharmacological inhibitor of histone acetyltransferase activity (Eliseeva et al., 2007). Confluent cultures were pretreated with anacardic acid, followed by incubation with TGF-β. Pharmacological inhibition of HAT activity dramatically abrogated the stimulation of collagen expression induced by TGF-β (Fig. 6b). Taken together, these results indicate that enhanced p300 expression and HAT activity in TGF-β-stimulated fibroblasts resulted in increased histone H4 acetylation that was associated with, and directly responsible for, up-regulation of fibrotic gene expression in these cells.
Previous studies have identified an essential role for p300 acetyltransferase and its interaction with Smads in TGF-β-induced profibrotic responses (Czuwara-Ladykowska et al., 2002; Ghosh et al., 2004; Ghosh et al., 2009; Ghosh et al., 2001; Ghosh et al., 2000). Despite its critical role in modulating profibrotic responses elicited by TGF-β and other mediators, the regulation of p300 expression and activity, and the mechanisms underlying their derangement in fibrotic diseases, have received scant attention to date.
The present results reveal that levels of p300 are significantly elevated in lesional skin biopsies from patients with SSc. Moreover, the expression of p300 in explanted normal fibroblasts was markedly up-regulated by TGF-β. Stimulation involved the canonical Smad-independent ERK1/2 -mediated up-regulation of the early immediate transcription factor Egr-1, which then directly stimulated p300 gene transcription. Treatment of the fibroblasts with TGF-β also resulted in enhanced histone H4 hyperacetylation concomitant with increased p300 accumulation at the COL1A2 promoter. Moreover, pharmacological blockade of HAT activity using anacardic acid abrogated the stimulation of collagen gene expression elicited by TGF-β. Taken together with the previous demonstration that augmented p300 expression in fibroblasts sensitized them to the profibrotic effects of TGF-β, the present results provide previously unreported insight into the mechanism of fibrosis in SSc, and indicate a fundamental role of acetyltransferase p300-mediated histone modifications in mediating this process.
Elevated p300 levels were seen in the skin from mice with bone-marrow transplantation-induced chronic GVHD (Bhattacharyya et al., 2005). Similar up-regulation of p300 was also observed in the skin from mice with bleomycin-induced scleroderma (Wu M, Bhattacharrya S, Varga J; unpublished results). The expression of p300 is elevated in explanted SSc skin fibroblasts (Bhattacharyya et al., 2005). Other studies linking fibrosis and p300 showed that the activated SSc fibroblast phenotype was attributed to ligand-independent constitutive association of p300 with Smad2/3 and consequent transcriptional activation of target genes (Ihn et al., 2006). The mechanism accounting for the increased accumulation of p300 in the lesional SSc skin, and its persistence in explanted SSc fibroblasts, remain unknown. Of note, elevated p300 expression has been reported in fibrotic kidneys from patients with glomerulonephritis (Kassimatis et al., 2006), as well as in a mouse model of lung fibrosis (Liu et al., 2004). The levels of p300 are elevated in various tumors (Li et al., 2011a; Li et al., 2011b). Moreover, the relative tissue expression of p300 in these cancers correlates with tumor aggressiveness and survival, suggesting a potential role for p300 as a biomarker of disease severity. Importantly, selective inhibition of p300 acetyltransferase activity with a small molecule blocked profibrotic TGF-β responses in normal fibroblasts in the present studies, and was shown to be reduced the invasiveness of prostate cancer cells displaying elevated p300 (Santer et al., 2011). Taken together, these observations suggest that p300 plays a fundamental role in progression of fibrosis and cancer, and determining its levels may serve as disease biomarkers in these conditions.
Since TGF-β can stimulate collagen gene expression via both canonical and Smad-independent signaling pathways (Ghosh, 2002; Varga, 2002), we investigated the role of the TGF-β receptor kinase and activation of downstream Smads in p300 regulation. Surprisingly, we found that an ERK1/2 kinase inhibitor, but not an ALK5 inhibitor, blocked the stimulation of p300 by TGF-β. The early-immediate transcription factor Egr-1 plays an indispensible role in fibrogenesis, and its expression is constitutively elevated in SSc biopsies (Bhattacharyya et al., 2011). Egr-1 has been implicated in regulation of p300 expression in prostate cancer cells (Yu et al., 2004). In these cells, incubation with serum triggered a potent up-regulation of p300. We have shown previously that in normal skin fibroblasts, Egr-1 was rapidly and transiently induced by TGF-β via a Smad-independent pathway (Bhattacharyya et al., 2011; Chen et al., 2006). Egr-1 stimulated collagen transcription by binding to collagen promoter (Chen et al., 2006). Here we found that Egr-1 directly augmented p300 gene expression and further enhanced the TGF-β-induced stimulation. In contrast, TGF-β failed to stimulate p300 transcription from a promoter with Egr-1 binding sites disrupted. Based on these findings, we propose a complex signaling relay network. Since levels of Egr-1, p300 and collagen are all significantly elevated in lesional SSc tissues, the fibrogenic TGF-β → Egr-1 → p300 → HAT activity and chromatin remodeling → target gene transcription relay pathway is likely to contribute to the progression of fibrosis in a concerted way (Fig. 6c).
Taken together, these results demonstrate that p300, a ubiquitous transcriptional coactivator and epigenetic regulator that is required for optimal Smad-dependent profibrotic responses, is itself a target of TGF-β signaling. Lesional tissue levels of p300 are significantly elevated in mouse models of scleroderma and pulmonary fibrosis, as well as in SSc skin biopsies and explanted SSc skin fibroblasts. Induction of p300 by TGF-β is dependent on Egr-1, which directly binds to regulatory DNA elements in the p300 gene and stimulates its transcription. Augmented abundance of cellular p300 is associated with enhanced intensity of profibrotic TGF-β signaling due to increased histone H4 hyperacetylation and Smad-dependent transcription. Because the cellular availability of p300 governs the intensity of TGF-β responses, Egr-1-mediated up-regulation of p300 expression and epigenetic activity is expected to augment the stimulation of collagen and other fibrotic genes, and thus plays a vital role in the pathogenesis of fibrosis. Small molecules are available to selectively disrupt the histone acetylransefrase activity of p300. Inducing competition for limiting amounts of cellular p300 using agents that activate the AMP kinase pathways, cyclic AMP or PPAR-γ might represent alternate “drug repurposing” approaches for repressing p300 function. Therefore, blocking the stimulation of p300 expression or activity might represent innovative therapeutic strategies to control TGF-β-mediated fibrogenesis.
Skin biopsies were obtained from the dorsal forearm of five healthy adults, and the lesional skin of ten SSc patients (clinical characteristics in Supplemental table 1). Fibroblasts were explanted from biopsies of lesional skin from patients with dSSc and a healthy adult and studied at early passage. All skin biopsies were performed with written informed consent and in compliance with the Institutional (Boston University and Northwestern University) Review Board for Human Studies, in adherence to the Declaration of Helsinki Principles.
Primary cultures of dermal fibroblasts were established by explantation from neonatal foreskin or adult skin (Chen et al., 1999). Mouse embryonic fibroblasts explanted from Smad3−/− or wild-type embryos were maintained in Dulbecco’s modified Eagle medium. Culture and infection of Rat-12 cells harboring Tet-inducible p300 were described previously (Baluchamy et al., 2003). At confluence, cultures were incubated with indicated concentrations of TGF-β2 (Genzyme, Framingham, MA), the ALK5 inhibitor SB431542 (Glaxo SmithKline, King of Prussia, PA), the ERK1/2 kinase inhibitor PD98059 or U0126 (Sigma, St. Louis, MO), or actinomycin D (Cell Signaling, Beverly, MA). To reach maximum induction of fibrotic responses, 12.5 ng/ml TGF-β was used in selected experiments. The histone acetyltransferase inhibitor anacardic acid (EMD Millipore, Billerica, MA) was added to the cultures 60 min prior to TGF-β.
The pGL3 p300-luc, pGL3 p300-luc-abcdef, PCB-pCMV-Egr-1 and p300-specific ribozyme constructs were from Dr Adamson (Yu et al., 2004). Confluent foreskin fibroblasts were transiently cotransfected with reporter and expression vectors or empty vectors using Superfect reagent (Qiagen, Valencia, CA), and incubated with TGF-β2 (12.5 ng/ml) for up to 48 h. Transfection with pRLTK-luc was used as an internal control.
Confluent cultures of fibroblasts were incubated with TGF-β (12.5 ng/ml). Twenty-four h later, cultures were harvested and histones were extracted as described (Ghosh et al., 2007). Chromatin immunoprecipitation (ChIP) assays were performed using the EZ magna ChIP Assay Kit (Upstate/Millipore, Billerica, MA) as described (Ghosh et al., 2009). PCR amplification of the captured DNA sequences was performed using primers complementary to COL1A2 sequences flanking the Smad binding element.
Following incubation with TGF-β for indicated periods, adult human dermal fibroblasts, foreskin fibroblasts or rat fibroblasts were harvested and whole cell lysates were prepared using M-PER lysis buffer (Pierce, Rockford, IL). Equal aliquots of total proteins or acid-extracted histones were electrophoresed on 4–20% Tris-Glycine gradient gels (BIORAD, Hercules, CA), followed by immunoblot analysis using primary antibodies against phospho-ERK1 (Cell Signaling), p300 and actin (Santa Cruz), total histone H4 or acetylated histone H4 (Ac-H4) (Upstate/Millipore). Blots were washed with TBST buffer, followed by incubation with appropriate HRP-conjugated secondary antibodies, and antigen-antibody complexes were visualized by chemiluminescence (ECL Reagent, Amersham BioSciences, Piscataway, NJ). To quantify the bands obtained via Western blot, developed films were scanned in grayscale and analyzed by ImageJ software (http://rsb.info.nih.gov/ij/).
Sections of human skin biopsies were deparaffinized, rehydrated and blocked for 30 min with 3% bovine serum albumin in Tris-buffered saline (pH 7.4), and then incubated overnight with anti-p300 antibody (Santa Cruz). Slides were then incubated for 30 min with a biotinylated donkey anti-rabbit secondary antibody followed by streptavidin-linked alkaline-phosphatase (Jackson Immuno Research, West Grove, PA), or with alkaline phosphatase-conjugated anti-mouse/anti-rabbit antibody (DakoCytomation, Carpinteria, CA) for 30 min and detected with Fast Red (DakoCytomation). Quantification was performed by two independent observers, and the intensity of staining was recorded for at least 200 individual fibroblasts using a scale of 0–3 (0=no visible staining, 1=faint staining observable, 2= moderate staining, 3=strong staining). The average intensity of fibroblast staining was calculated based on images from random fields throughout the dermis of the whole tissue section.
To examine the role of Egr-1 in the regulation of p300 expression in vivo, six- to eight-week-old Egr-1 knockout mice in the C57BL/6 background (Wu et al., 2009) and wildtype littermates were used under protocols institutionally approved by the Northwestern University Animal Care and Use Committee. Mice were injected with TGF-β (250 ng) or PBS. After 48 h, mice were sacrificed, 4 μm sections from dorsal skin were deparaffinized, rehydrated, and immersed in TBS-T buffer, and treated with target retrieval solution (DAKO). Sections were incubated with anti-p300 antibody (Santa Cruz), and bound antibodies were detected using Alexa®488 conjugated donkey-anti-rabbit antibody (Invitrogen). Rabbit control IgG was used as negative controls. Sections were counterstained with 4′-6-diamidino-2-phenylindole (DAPI) for nuclei. Following washing, slides were examined under a Zeiss UV Meta 510 confocal microscope (Carl Zeiss, Jena, Germany).
Total RNA was isolated from confluent fibroblasts using TRIZOL reagent (Life Technologies, Grand Island, NY), and examined by Northern analysis or RT-PCR (Bhattacharyya et al., 2005). Reverse transcription were performed using SuperScript First-strand synthesis system (Invitrogen) according to the manufacturer’s protocol. Primers (Sigma Genosys, Woodlands, TX) for PCR were as following: p300, sense 5′-CTTTACCGTCAGGATCCAG-3′, antisense 5′-AGTATTTGTATACCCGT ATG-3′; actin, sense 5′-ATCTGGCACCACACCTTCTACAATGAG CTGCG-3′, antisense 5′-CGTCATACTCCTGCTTGTGATCCACATCTGC-3′. For real-time qPCR, reactions were performed on ABI-Prism 7300 sequence detection PCR machine (Applied Biosystem, Forster City, CA) according to the manufacturer’s protocol. The primer sequences are available upon request. Relative mRNA expression levels were normalized with GAPDH mRNA levels and determined by calculating ΔΔCt.
The data are presented as the means ± S.D or means ± SEM. Statistical differences between experimental and control groups were determined by analysis of variance. Values of p<0.05 by Student t-test were considered significant.
FN3CONFLICT OF INTREST
The authors state no conflict of interest.
We are grateful to Eileen Adamson (Burnham Institute, CA) for helpful suggestions and for providing plasmids. This work was supported by grants from the National Institutes of Health (AR42309 and CA74403) and the Scleroderma Foundation.
|Baluchamy S,Rajabi HN,Thimmapaya R,Navaraj A,Thimmapaya B. Year: 2003Repression of c-Myc and inhibition of G1 exit in cells conditionally overexpressing p300 that is not dependent on its histone acetyltransferase activityProceedings of the National Academy of Sciences of the United States of America1009524912883011|
|Bhattacharyya S,Ghosh AK,Pannu J,Mori Y,Takagawa S,Chen G,et al. Year: 2005Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor betaArthritis and rheumatism5212485815818659|
|Bhattacharyya S,Sargent JL,Du P,Lin S,Tourtellotte WG,Takehara K,et al. Year: 2011Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosisPloS one6e2308221931594|
|Chen SJ,Ning H,Ishida W,Sodin-Semrl S,Takagawa S,Mori Y,et al. Year: 2006The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expressionThe Journal of biological chemistry281211839716702209|
|Chen SJ,Yuan W,Mori Y,Levenson A,Trojanowska M,Varga J. Year: 1999Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3The Journal of investigative dermatology11249579886263|
|Czuwara-Ladykowska J,Sementchenko VI,Watson DK,Trojanowska M. Year: 2002Ets1 is an effector of the transforming growth factor beta (TGF-beta) signaling pathway and an antagonist of the profibrotic effects of TGF-betaThe Journal of biological chemistry2772039940811919190|
|Eliseeva ED,Valkov V,Jung M,Jung MO. Year: 2007Characterization of novel inhibitors of histone acetyltransferasesMolecular cancer therapeutics62391817876038|
|Ghosh AK. Year: 2002Factors involved in the regulation of type I collagen gene expression: implication in fibrosisExp Biol Med (Maywood)2273011411976400|
|Ghosh AK,Bhattacharyya S,Varga J. Year: 2004The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cellsThe Journal of biological chemistry279474556315345715|
|Ghosh AK,Bhattacharyya S,Wei J,Kim S,Barak Y,Mori Y,et al. Year: 2009Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivatorFASEB journal: official publication of the Federation of American Societies for Experimental Biology2329687719395477|
|Ghosh AK,Mori Y,Dowling E,Varga J. Year: 2007Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: involvement of Sp1Biochemical and biophysical research communications354420617234156|
|Ghosh AK,Varga J. Year: 2007The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosisJournal of cellular physiology2136637117559085|
|Ghosh AK,Yuan W,Mori Y,Chen S,Varga J. Year: 2001Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivatorsThe Journal of biological chemistry27611041811134049|
|Ghosh AK,Yuan W,Mori Y,Varga J. Year: 2000Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivatorsOncogene1935465510918613|
|Giles RH,Peters DJ,Breuning MH. Year: 1998Conjunction dysfunction: CBP/p300 in human diseaseTrends in genetics: TIG14178839613201|
|Goodman RH,Smolik S. Year: 2000CBP/p300 in cell growth, transformation, and developmentGenes & development1415537710887150|
|Ihn H,Yamane K,Asano Y,Jinnin M,Tamaki K. Year: 2006Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblastsRheumatology (Oxford)451576516319104|
|Iyer NG,Ozdag H,Caldas C. Year: 2004p300/CBP and cancerOncogene2342253115156177|
|Janknecht R. Year: 2002The versatile functions of the transcriptional coactivators p300 and CBP and their roles in diseaseHistology and histopathology176576811962765|
|Kaimori A,Potter JJ,Choti M,Ding Z,Mezey E,Koteish AA. Year: 2010Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytesHepatology5210334520564330|
|Kassimatis TI,Giannopoulou I,Koumoundourou D,Theodorakopoulou E,Varakis I,Nakopoulou L. Year: 2006Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: correlation with renal injuryJournal of cellular and molecular medicine109082117125594|
|Kraus WL,Kadonaga JT. Year: 1998p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiationGenes & development12331429450928|
|Li M,Luo RZ,Chen JW,Cao Y,Lu JB,He JH,et al. Year: 2011aHigh expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinomaJournal of translational medicine9521205329|
|Li Y,Yang HX,Luo RZ,Zhang Y,Li M,Wang X,et al. Year: 2011bHigh expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinomaThe Annals of thoracic surgery911531821524463|
|Lim JY,Oh MA,Kim WH,Sohn HY,Park SI. Year: 2012AMP-activated protein kinase inhibits TGF-beta-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300Journal of cellular physiology2271081921567395|
|Liu T,Dhanasekaran SM,Jin H,Hu B,Tomlins SA,Chinnaiyan AM,et al. Year: 2004FIZZ1 stimulation of myofibroblast differentiationThe American journal of pathology16413152615039219|
|Petrij F,Giles RH,Dauwerse HG,Saris JJ,Hennekam RC,Masuno M,et al. Year: 1995Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBPNature376348517630403|
|Roelfsema JH,White SJ,Ariyurek Y,Bartholdi D,Niedrist D,Papadia F,et al. Year: 2005Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause diseaseAmerican journal of human genetics765728015706485|
|Saha RN,Pahan K. Year: 2006HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasisCell death and differentiation135395016167067|
|Santer FR,Hoschele PP,Oh SJ,Erb HH,Bouchal J,Cavarretta IT,et al. Year: 2011Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell linesMolecular cancer therapeutics1016445521709130|
|Varga J. Year: 2002Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosisArthritis and rheumatism4617031312124852|
|Vo N,Goodman RH. Year: 2001CREB-binding protein and p300 in transcriptional regulationThe Journal of biological chemistry27613505811279224|
|Wu M,Melichian DS,Chang E,Warner-Blankenship M,Ghosh AK,Varga J. Year: 2009Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gammaThe American journal of pathology1745193319147827|
|Yokomizo C,Yamaguchi K,Itoh Y,Nishimura T,Umemura A,Minami M,et al. Year: 2011High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cellsCancer letters310140721764211|
|Yu J,de Belle I,Liang H,Adamson ED. Year: 2004Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responsesMolecular cell15839415225550|
Keywords: Acetyltransferase p300, TGF-β, fibroblast, systemic sclerosis, fibrosis, EGR-1, epigenetics.
Previous Document: ?-Catenin Promotes the Differentiation of Epidermal Langerhans Dendritic Cells.
Next Document: Catalytic mechanism of cytochrome P450 for N-methylhydroxylation of nicotine: reaction pathways and ...